Brainstorm Cell Therapeutics Inc (BCLI)

NASDAQ
Currency in USD
2.190
+0.030(+1.39%)
Closed
After Hours
2.300+0.110(+5.023%)
BCLI Scorecard
Full Analysis
Quickly burning through cash
Unusual Post-Market activity
Fair Value
Day's Range
2.0502.270
52 wk Range
1.05011.890
Key Statistics
Edit
Prev. Close
2.16
Open
2.11
Day's Range
2.05-2.27
52 wk Range
1.05-11.89
Volume
51.58K
Average Volume (3m)
107.25K
1-Year Change
-53.94%
Book Value / Share
-1.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BCLI Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
14.450
Upside
+559.82%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week
Show more

Brainstorm Cell Therapeutics Inc Company Profile

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Compare BCLI to Peers and Sector

Metrics to compare
BCLI
Peers
Sector
Relationship
P/E Ratio
−0.9x−2.4x−0.7x
PEG Ratio
−0.02−0.090.00
Price/Book
−2.1x2.4x2.6x
Price / LTM Sales
-32.8x3.1x
Upside (Analyst Target)
356.6%215.7%49.0%
Fair Value Upside
Unlock−0.9%7.4%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 14.450
(+559.82% Upside)

Earnings

Latest Release
Nov 14, 2024
EPS / Forecast
-1.80 / -0.04
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

1.930
AMPG
-1.03%
4.400
NVNI
+195.30%
2.100
OPTX
-2.33%
1.8200
PBM
+6.43%
0.4263
GWAV
-2.27%

FAQ

What Is the Brainstorm Cell Therapeutics (BCLI) Stock Price Today?

The Brainstorm Cell Therapeutics stock price today is 2.19

What Stock Exchange Does Brainstorm Cell Therapeutics Trade On?

Brainstorm Cell Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Brainstorm Cell Therapeutics?

The stock symbol for Brainstorm Cell Therapeutics is "BCLI."

What Is the Brainstorm Cell Therapeutics Market Cap?

As of today, Brainstorm Cell Therapeutics market cap is 12.49M.

What is Brainstorm Cell Therapeutics Earnings Per Share?

The Brainstorm Cell Therapeutics EPS is -3.19.

From a Technical Analysis Perspective, Is BCLI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.